Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth-Reference-Cited by-同舟云学术

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

Published:2017-07-05 Issue:6 Volume:178 Page:896-905
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Dimopoulos Meletios A.¹^ORCID,Lonial Sagar²,White Darrell³,Moreau Philippe⁴^ORCID,Palumbo Antonio⁵,San-Miguel Jesus⁶^ORCID,Shpilberg Ofer⁷,Anderson Kenneth⁸,Grosicki Sebastian⁹,Spicka Ivan¹⁰,Walter-Croneck Adam¹¹,Magen Hila¹²,Mateos Maria-Victoria¹³,Belch Andrew¹⁴,Reece Donna¹⁵,Beksac Meral¹⁶,Bleickardt Eric¹⁷,Poulart Valerie¹⁸,Sheng Jennifer¹⁹,Sy Oumar²⁰,Katz Jessica²¹,Singhal Anil²²,Richardson Paul²³

Affiliation:

1. Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Athens Greece

2. Department of Hematology and Medical Oncology; Winship Cancer Institute; Emory University School of Medicine; Atlanta GA USA

3. Division of Hematology; Queen Elizabeth II Health Sciences Centre and Dalhousie University; Halifax NS Canada

4. Department of Haematology; University Hospital; Nantes France

5. Myeloma Unit; Division of Haematology; University of Torino; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Torino Italy

6. Clinica Universidad de Navarra; Investigación Médica Aplicada; IDISNA; CIBERONC; Pamplona Spain

7. Institute of Haematology; Assuta Medical Centers; Tel Aviv Israel

8. Division of Hematologic Oncology; Dana-Farber Cancer Institute; Boston MA USA

9. Department of Cancer Prevention; Medical University of Silesia; Katowice Poland

10. 1st Department of Medicine - Department of Haematology; First Faculty of Medicine; Charles University and General Teaching Hospital in Prague; Prague Czech Republic

11. Department of Haemato-oncology and Bone Marrow Transplantation; Medical University of Lublin; Lublin Poland

12. Davidoff Cancer Center; Rabin Medical Center; Petah Tikva Israel

13. Haematology Department; University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca (IBSAL); Salamanca Spain

14. Department of Oncology; Cross Cancer Institute and University of Alberta; Edmonton AB Canada

15. Department of Medical Oncology and Haematology; Princess Margaret Cancer Centre; Toronto ON Canada

16. Department of Haematology; Ankara University; Ankara Turkey

17. Oncology Clinical Development; Bristol-Myers Squibb; Lawrenceville NJ USA

18. Global Biostatistics; Bristol-Myers Squibb; Lawrenceville NJ USA

19. Clinical Pharmacology & Pharmacometrics; Bristol-Myers Squibb; Lawrenceville NJ USA

20. Global Biometric Sciences; Bristol-Myers Squibb; Lawrenceville NJ USA

21. Global Clinical Research (Research and Development Oncology); Bristol-Myers Squibb; Lawrenceville NJ USA

22. AbbVie Biotherapeutics Inc. (ABR); Redwood City CA USA

23. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA

Funder

Bristol-Myers Squibb in collaboration with AbbVie Biotherapeutics

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14787/fullpdf

Reference14 articles.

1. Amgen 2016 FDA approves new Kyprolis ® (carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma http://www.amgen.com/media/news-releases/2016/01/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/

2. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC;Collins;Cancer Immunology, Immunotherapy,2013

3. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma;Dimopoulos;Leukemia,2009

4. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos;New England Journal of Medicine,2016

5. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Onco-Hypertension: Anticancer Therapy-Associated Hypertension;Hypertension;2024

2. Cardiovascular toxicity from therapies for light chain amyloidosis;Frontiers in Cardiovascular Medicine;2023-07-05

3. Recomendações do Grupo Português do Mieloma Múltiplo para Tratamento do Mieloma Múltiplo;Acta Médica Portuguesa;2023-07-03

4. Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma;Cancer Immunology, Immunotherapy;2023-05-20

5. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies;Blood Cancer Journal;2023-05-19